Brean Capital Assumes Nektar Therapeutics to Buy

Brokerage firm Brean Capital Assumes its rating on Nektar Therapeutics(NASDAQ:NKTR). The shares have been rated Buy. The rating by Brean Capital was issued on Sep 30, 2016.

Nektar Therapeutics (NKTR) shares turned negative on Tuesdays trading session with the shares closing down -0.54 points or -3.09% at a volume of 8,86,073. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $17.69. The peak price level was also seen at $17.69 while the days lowest was $16.82. Finally the shares closed at $16.94. The 52-week high of the shares is $19.98 while the 52-week low is $9.92. According to the latest information available, the market cap of the company is $2,316 M.

Nektar Therapeutics(NKTR) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $32.77M. Analysts had an estimated revenue of $34.17M. Earnings per share were $-0.36. Analysts had estimated an EPS of $-0.30.

Several Insider Transactions has been reported to the SEC. On Sep 19, 2016, Lutz Lingnau (director) sold 9,000 shares at $19.06 per share price.Also, On Sep 19, 2016, Christopher A Kuebler (director) sold 7,500 shares at $19.13 per share price.On Sep 19, 2016, Robert Chess (director) sold 12,000 shares at $19.21 per share price, according to the Form-4 filing with the securities and exchange commission.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Nektar Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nektar Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.